Investments	12 Months Ended
Jun. 30, 2020
Investments [Abstract]
Investments	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:13pt;"><font style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-style:normal;font-weight:bold;text-decoration:none;">. Investments</font><font style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-style:normal;font-weight:bold;text-decoration:none;"> </font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;">In August 2018, we sold our </font><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;">98 percent</font><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> equity interest in naviHealth Holdings, LLC ("naviHealth") to investor entities controlled by Clayton, Dubilier & Rice in exchange for cash proceeds of </font><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;">$737 million</font><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> (after adjusting for certain fees and expenses) and a </font><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;">40 percent</font><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> equity interest in a partnership that owns </font><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;">100 percent</font><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> of the equity interest of naviHealth. We also have certain call rights to reacquire naviHealth. We have accounted for this investment using the equity method of accounting and on a one-month reporting lag.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;">During the fiscal year ended </font><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;">June 30, 2019</font><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, we recognized a pre-tax gain of </font><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;">$508 million</font><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> related to this divestiture in impairments and (gain)/loss on disposal of assets in our consolidated statements of earnings/(loss). The carrying value of this investment was </font><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;">$334 million</font><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> as of </font><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;">June 30, 2019</font><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;">In May 2020, we sold our </font><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;">40 percent</font><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> equity interest in a partnership that owns </font><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;">100 percent</font><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> of the equity interest of naviHealth in exchange for cash proceeds of [] and recognized a gain of [] related to this disposal in gain on sale of naviHealth stock in our consolidated statements of earnings/(loss). During the three and twelve months ended </font><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;">June 30, 2020</font><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, our proportionate share of naviHealth’s net loss, which was recorded in other (income)/ expense, net in the consolidated statements of earnings/(loss), was immaterial.</font></div></div>

Investments

12 Months Ended

Jun. 30, 2020

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:13pt;">. Investments </div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;">In August 2018, we sold our 98 percent equity interest in naviHealth Holdings, LLC ("naviHealth") to investor entities controlled by Clayton, Dubilier & Rice in exchange for cash proceeds of $737 million (after adjusting for certain fees and expenses) and a 40 percent equity interest in a partnership that owns 100 percent of the equity interest of naviHealth. We also have certain call rights to reacquire naviHealth. We have accounted for this investment using the equity method of accounting and on a one-month reporting lag.</div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;">During the fiscal year ended June 30, 2019, we recognized a pre-tax gain of $508 million related to this divestiture in impairments and (gain)/loss on disposal of assets in our consolidated statements of earnings/(loss). The carrying value of this investment was $334 million as of June 30, 2019. </div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;">In May 2020, we sold our 40 percent equity interest in a partnership that owns 100 percent of the equity interest of naviHealth in exchange for cash proceeds of [] and recognized a gain of [] related to this disposal in gain on sale of naviHealth stock in our consolidated statements of earnings/(loss). During the three and twelve months ended June 30, 2020, our proportionate share of naviHealth’s net loss, which was recorded in other (income)/ expense, net in the consolidated statements of earnings/(loss), was immaterial.</div></div>